Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company crawled time : 22:00 save search
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Pharmaceutical Market In Canada size is set to grow by USD 8.73 bn from 2024-2028, Abbott Laboratories, AbbVie Inc. & Amgen Inc., and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-03-27 (Crawled : 22:00) - prnewswire.com
GLAXF | News | $20.305 0.52% -14.18% 0
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -1.17%
H: 0.0%
C: -0.89%
AZNCF | News | $138.73 1.86% -4.19% 0
|
Health Technology
|
| O: 0.89%
H: 0.78%
C: 0.78%
NVSEF | News | $95.11 5.4% 6.88% 0
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
GSK | News | $40.59 2.11% 0.1% 1.3K
|
Health Technology
|
| O: 0.02%
H: 0.51%
C: -0.3%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: 0.36%
H: 0.72%
C: 0.61%
ABT | News | $107.07 -0.2% 0.18% 3.8M
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: 0.0%
AZN | News | $70.13 2.31% 2.24% 11K
|
Health Technology
|
| O: -0.12%
H: 0.25%
C: -0.63%
AMGN | News | $271.91 1.11% 1.12% 560
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
abbvie set canada key market
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
Published: 2023-12-15 (Crawled : 22:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.6%
H: 0.57%
C: -0.53%
report results
FDA Roundup: November 17, 2023
Published: 2023-11-17 (Crawled : 22:00) - prnewswire.com
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
| Email alert
Add to watchlist
fda
Global Dermatology Drugs Market Set to Skyrocket, Anticipated Valuation of $50.47 Billion by 2032
Published: 2023-09-22 (Crawled : 22:00) - prnewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 5.4% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.12 0.82% 0.59% 440K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
| Email alert
Add to watchlist
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $271.91 1.11% 1.12% 560
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.45 -2.76% -0.24% 2.1M
|
Health Technology
| Email alert
Add to watchlist
global set market
Innovative Gelatin Capsules Transforming Pharmaceutical Industry: A Look into the Future
Published: 2023-09-22 (Crawled : 22:00) - prnewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 5.4% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.12 0.82% 0.59% 440K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
| Email alert
Add to watchlist
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $271.91 1.11% 1.12% 560
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.45 -2.76% -0.24% 2.1M
|
Health Technology
| Email alert
Add to watchlist
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma
Published: 2023-06-27 (Crawled : 22:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
fotivda renal cell study
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.28%
H: 0.42%
C: -0.05%
fda approval cell therapy
Peptide Therapeutics Global Market Report 2023: Increase in the Prevalence of Chronic Diseases Drives Growth
Published: 2023-06-01 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 1.86% -4.19% 0
|
Health Technology
|
| O: -0.74%
H: 1.4%
C: 0.35%
NVSEF | News | $95.11 5.4% 6.88% 0
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: 1.32%
H: 0.31%
C: 0.12%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.6%
H: 1.07%
C: 0.29%
NVO | News | $125.26 2.08% 1.22% 22K
|
Health Technology
|
| O: -1.84%
H: 1.62%
C: 1.33%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: 1.03%
H: 0.84%
C: 0.82%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.37%
H: 1.34%
C: 1.14%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
AZN | News | $70.13 2.31% 2.24% 11K
|
Health Technology
|
| O: 0.11%
H: 0.69%
C: -0.45%
report global therapeutics growth market
Global Blood Cancer Drugs Market Report 2023: Increasing Prevalence of Blood Cancer Cases Drives Growth
Published: 2023-05-16 (Crawled : 22:00) - prnewswire.com
AZNCF | News | $138.73 1.86% -4.19% 0
|
Health Technology
|
| O: -1.32%
H: 0.92%
C: -1.34%
JNJ | News | $149.12 0.82% 0.59% 440K
|
Health Technology
|
| O: 0.28%
H: 0.17%
C: -0.5%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.06%
H: 0.43%
C: -0.79%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: -0.19%
H: 0.35%
C: 0.23%
AZN | News | $70.13 2.31% 2.24% 11K
|
Health Technology
|
| O: 0.07%
H: 0.03%
C: -0.84%
AMGN | News | $271.91 1.11% 1.12% 560
|
Health Technology
|
| O: -0.82%
H: 0.03%
C: -0.44%
report cancer blood global growth market
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-29 (Crawled : 22:00) - globenewswire.com
FNCTF | News | $11.16 1.13% -20.84% 0
|
Communications
|
| O: 1.48%
H: 0.0%
C: 0.0%
GNMSF | News | $289.67 1.8% 3.83% 0
|
Health Technology
|
| O: 0.0%
H: 1.69%
C: 1.42%
BOLT | $1.11 1.77% 39K
|
|
| O: 5.43%
H: 0.74%
C: -1.47%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.29%
H: 0.22%
C: -0.26%
GMAB | News | $28.97 0.94% 0.93% 2
|
Health Technology
|
| O: 0.37%
H: 0.05%
C: -0.4%
business year update financial results
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Published: 2022-06-15 (Crawled : 22:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.4%
H: 0.6%
C: -0.19%
Worldwide Orphan Drugs Industry to 2027 - Featuring Jazz Pharmaceuticals, Merck & Co and Pfizer Among Others
Published: 2021-10-07 (Crawled : 22:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: 3.76%
H: 0.0%
C: 0.0%
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.7%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
JNJ | News | $149.12 0.82% 0.59% 440K
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.24%
H: 0.2%
C: -2.73%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
JAZZ | $108.83 -1.01% -1.04% 1
|
Health Technology
|
| O: -0.04%
H: 1.01%
C: -1.78%
BIIB | $194.11 -0.14% -0.15% 120
|
Health Technology
|
| O: -0.11%
H: 0.54%
C: -0.56%
AMGN | News | $271.91 1.11% 1.12% 560
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
orphan drug drug
Global Active Pharmaceutical Ingredients (API) Market Report 2021
Published: 2021-10-05 (Crawled : 22:00) - prnewswire.com
VTRS | News A | $11.25 -0.13% 4.1M
|
Health Technology
|
| O: -0.74%
H: 1.31%
C: 0.3%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.07%
H: 0.2%
C: 0.14%
ALB | News | $112.29 0.13% 0.15% 2M
|
Process Industries
|
| O: -1.07%
H: 1.26%
C: 1.08%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.87%
H: 0.8%
C: 0.63%
HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced Melanoma
Published: 2021-09-21 (Crawled : 22:00) - prnewswire.com
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.28%
H: 0.26%
C: -0.58%
nivolumab
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
Published: 2021-08-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: -0.24%
H: 0.27%
C: 0.0%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.38%
H: 0.07%
C: -0.97%
EXEL | $22.87 1.55% 1.49% 1.5M
|
Health Technology
|
| O: -0.37%
H: 2.23%
C: 0.27%
treatment renal approval cell carcinoma nivolumab
Outlook on the Multiple Myeloma Drugs Global Market to 2026 - by Therapy, Drug Type, End-user, Distribution Channel and Region
Published: 2021-08-25 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: -0.65%
H: 0.18%
C: -0.06%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: -0.33%
H: 0.26%
C: 0.03%
JNJ | News | $149.12 0.82% 0.59% 440K
|
Health Technology
|
| O: -0.16%
H: 0.44%
C: -0.37%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.25%
H: 0.49%
C: -0.65%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.37%
H: 0.19%
C: -0.25%
AMGN | News | $271.91 1.11% 1.12% 560
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: -0.27%
therapy distribution drug
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-05 (Crawled : 22:00) - biospace.com/
TEVA | $12.88 0.16% -0.08% 7.9M
|
Health Technology
|
| O: 0.5%
H: 2.84%
C: -0.7%
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.36%
NKTR | News | $1.36 9.68% 9.49% 0
|
Health Technology
|
| O: 0.77%
H: 1.33%
C: 0.83%
EXEL | $22.87 1.55% 1.49% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.25%
financial results results
Insights on the Mantle Cell Lymphoma Treatment Global Market to 2029 - Key Drivers, Challenges and Opportunities
Published: 2021-06-17 (Crawled : 22:00) - prnewswire.com
GSK | News | $40.59 2.11% 0.1% 1.3K
|
Health Technology
|
| O: -1.48%
H: 0.4%
C: -0.33%
LLY | News | $731.33 0.69% 0.73% 12K
|
Health Technology
|
| O: -0.8%
H: 0.28%
C: -0.85%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: -0.55%
H: 0.5%
C: 0.11%
GILD | $66.95 0.29% 0.28% 2.1K
|
Health Technology
|
| O: -0.33%
H: 0.27%
C: -0.58%
treatment
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1
Published: 2021-05-27 (Crawled : 22:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.26%
H: 0.53%
C: -0.89%
food treatment drug
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
CANG | $1.34 -4.29% 14.93% 120K
|
Technology Services
AZTR 4 | $0.195 13.85% 42K
|
n/a
TOVX | News | $0.411 -1.01% 12.9% 230K
|
Manufacturing
IBRX | $4.94 -6.26% 10.83% 4.5M
|
Manufacturing
MSTR M | $1324.01 12.77% 10.65% 26K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.